bioMerieux, Cepheid, NorChip A/S deal

BIM and CEPH will jointly develop diagnostics for sepsis and methicillin-resistant S. aureus (MRSA) on CPHD's GeneXpert nucleic acid analysis system. CPHD will manufacture the sepsis assays, which BIM will distribute on an exclusive worldwide basis. CPHD also received a non-exclusive worldwide license to BIM's MRSA patents. CPHD will develop, manufacture and market the MRSA products, which include bacterial and fungal identification assays, and a series of genetic markers for antibiotic resistance. Financial terms were not disclosed. ...